Literature DB >> 9572410

Synchronization of endogenous and exogenous FSH stimuli in controlled ovarian hyperstimulation (COH).

D de Ziegler1, A S Jääskeläinen, P A Brioschi, R Fanchin, C Bulletti.   

Abstract

We have previously observed that exogenous oestradiol can delay the intercycle increase in plasma follicle stimulating hormone (FSH). The increase in plasma FSH that follows discontinuation of exogenous oestradiol peaks after 3 days. We have now studied the possibility of using exogenous oestradiol to synchronize the increase in endogenous FSH with the onset of human menopausal gonadotrophin (HMG) treatment in controlled ovarian hyperstimulation (COH). A total of 30 women aged 35.1+/-6.3 years (mean+/-SD) undergoing ovarian stimulation received 2 mg of oestradiol valerate twice daily starting on day 25 of the previous menstrual cycle until the first Tuesday following menses. Ovarian stimulation was initiated 3 days later. On the last day of oestradiol treatment, plasma oestradiol, FSH and luteinizing hormone (LH) (mean+/-SEM) were 566+/-53 (pmol/l), 3.8+/-0.4 (IU/l) and 5.5+/-0.8 (IU/l) respectively. After 3 days, the FSH and LH (mean+/-SEM) had increased to 6.7+/-0.7 and 6.9+/-0.7 (IU/l) respectively while oestradiol decreased to 251+/-29 (pmol/l). The mean number (+/-SEM) of HMG ampoules used was 25.1+/-2.7 and treatment lasted 11.3+/-0.9 days. Five women became pregnant for a pregnancy rate (ongoing) of 19 (15)%. If all women aged >40 years (six women who did not become pregnant) were excluded from analysis the pregnancy rate (ongoing) was 24 (19%). These results indicate that exogenous oestradiol can safely be used for the synchronization of endogenous and exogenous FSH stimuli in COH. This approach provides the practical advantage of permitting an advanced timing of the onset of COH treatments when gonadotrophin-releasing hormone (GnRH) agonists are not used, which improves treatment convenience for patients and team members alike. Further development of this model may enable control of the onset of natural cycles which may find practical applications for timing assisted reproductive techniques (intrauterine insemination or in-vitro fertilization) in the natural cycle.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9572410     DOI: 10.1093/humrep/13.3.561

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  6 in total

1.  Precycle Estradiol in Synchronization and Scheduling of Antagonist Cycles.

Authors:  Shilpa Saple; Mukesh Agrawal; Simi Kawar
Journal:  J Obstet Gynaecol India       Date:  2016-04-29

Review 2.  Cycle cancellation and pregnancy after luteal estradiol priming in women defined as poor responders: a systematic review and meta-analysis.

Authors:  Kasey A Reynolds; Kenan R Omurtag; Patricia T Jimenez; Julie S Rhee; Method G Tuuli; Emily S Jungheim
Journal:  Hum Reprod       Date:  2013-07-25       Impact factor: 6.918

3.  Luteal phase oestradiol administration in ovarian stimulation cycles with GnRH antagonist is comparable to the GnRH agonist (long) protocol.

Authors:  J S Cunha Filho; L F Terres; F Holanda; F Freitas; C Glitz; V K Genro; E Arbo
Journal:  J Assist Reprod Genet       Date:  2007-07-17       Impact factor: 3.412

4.  Cycle scheduling for in vitro fertilization with oral contraceptive pills versus oral estradiol valerate: a randomized, controlled trial.

Authors:  Erik E Hauzman; Azucena Zapata; Alfonso Bermejo; Carlos Iglesias; Antonio Pellicer; Juan A Garcia-Velasco
Journal:  Reprod Biol Endocrinol       Date:  2013-09-28       Impact factor: 5.211

5.  Pretreatment of normal responders in fresh in vitro fertilization cycles: A comparison of transdermal estradiol and oral contraceptive pills.

Authors:  Nigel Pereira; Allison C Petrini; Zhen N Zhou; Jovana P Lekovich; Isaac Kligman; Zev Rosenwaks
Journal:  Clin Exp Reprod Med       Date:  2016-12-26

6.  Comparison of pre-treatment with OCPs or estradiol valerate vs. no pre-treatment prior to GnRH antagonist used for IVF cycles: An RCT.

Authors:  Ensieh Shahrokh Tehrani Nejad; Fatemeh Bakhtiari Ghaleh; Bita Eslami; Fedyeh Haghollahi; Maryam Bagheri; Masoumeh Masoumi
Journal:  Int J Reprod Biomed       Date:  2018-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.